Normalization of Left Ventricular Ejection Fraction and Incidence of Appropriate Anti- @entity591 Therapy in XXXX with Implantable Cardioverter Defibrillator for Primary Prevention of @entity944 .

@entity1 @entity308 @entity944 @entity737 @entity591 @entity1002
BACKGROUND: @entity1 with severely @entity308 @entity1002 ( @entity1002 ) receive @entity737 ( @entity737 ) for the primary prevention of @entity944 . In some @entity1 , however, @entity1002 may improve or even normalize over time. Limited data are available on the incidence of appropriate anti- @entity591 therapy including pacing and shock in these @entity1 . METHODS: We retrospectively identified consecutive @entity1 at our institution with an @entity737 for primary prevention who had @entity1002 measurement available at initial implantation and at the time of generator replacement. None of these @entity1 had ever received appropriate anti- @entity591 therapy before generator replacement. The incidence of appropriate anti- @entity591 therapy after generator replacement was assessed. RESULTS: Of the 125 @entity1 received generator replacement, 53 (42%) @entity1 received an @entity737 and 72 (58%) received a cardiac resynchronization therapy-defibrillator (CRT-D). Among them, 30 (21%) had @entity1002 normalized to >=  50%, 25 (17%) had @entity1002 partially improved to 36-49%, and 70 (63%) had @entity1002 that remained @entity308 at  <= 35%. During an overall follow-up period of 25    18 months, none of the individuals with normalized @entity1002 experienced appropriate anti- @entity591 therapy regardless of @entity737 or CRT-D. Meanwhile, 20% of @entity1 with @entity1002 at 36-49% and 14% of @entity1 with @entity1002 at  <= 35% received appropriate @entity737 therapy. The omnibus p-value for any differences between the three @entity1002 groups was 0.046 for the entire cohort, 0.01 for @entity737 and 0.15 for CRT-D @entity1 . CONCLUSION: These preliminary data suggest that @entity1 with reduced @entity1002 and primary prevention @entity737 who normalize their @entity1002 over time may be at lower risk of appropriate anti- @entity591 therapy.
